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ABSTRACT
Molecular Docking, Synthesis, and Evaluation of Pyrrolo[2,1-c][1,4]benzodiazepines
Derivatives as Non-β-lactam β-lactamases Inhibitors.
by
Joseph O. Osazee
Our research aim was to design, synthesize, and study the competitive enzyme inhibition kinetics
of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) derivatives as potential non-β-lactam β-lactamase
inhibitors. All compounds (1-13) passed the Lipinski’s rule of 5 test and were docked into the
active site of TEM-1 β-lactamase. PBD derivatives 1-7 were synthesized in high yields and
tested for their potency against TEM-1 and P99 β-lactamases. Kinetic data showed that
compounds 1, 4, 5, and 7 possessed inhibitory activity against TEM-1 ranging from 4-34 %.
Docking results revealed significant interactive spanning of the active site of TEM-1 by PBDs.
The limited inhibitory activity of the compounds, 1-7 could be attributed to the lack of solubility
and bulky nature of the molecules, thus limiting the optimal ligand-enzyme interactions. 1,2,4Oxadiazolinones (8-13) were further synthesized to reduce the steric hindrance of the PBD
scaffolds while promoting the electrophilicity of the potentially active lactam and also evaluated
for potency.
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW
History of β-lactam Antibiotics
β-lactam antibiotics have continued to be the most popular drug for treating bacterial
infections since their discovery in 1928 by Fleming and their introduction as antibacterial agents
in the early 1950.1 Most commonly used β-lactam drugs today stem from the original discovery
and development of natural products from microorganisms like penicillin, cephalosporin, and
other β-lactam based antibiotics (Figure 1).1,2 However, soon after its commercialization, βlactamases secreting penicillin resistant strains of Staphylococcus aureus were isolated.3 The
introduction of methicillin (a β-lactamase-insensitive semi-synthetic penicillin), to curb the
resistance problem resulted in the evolution of another resistant strain known as methicillinresistant Staphylococcus aureus (MRSA).4

Figure 1: Some β-lactam Antibiotics

Resistance to β-lactams was easy for bacteria as all β-lactams shared the same mode of
action which was the inhibition of bacterial cell wall synthesis by forming a stable covalent
adduct with the active site serine residues of penicillin-binding proteins (PBPs). The PBPs are
often divided into two classes: the high molecular weight PBPs (HMW-PBPs) and the low18

molecular weight PBPs (LMW-PBPs). The HMW-PBPs are further divided into two classes, A
and B while the LMW-PBPs are divided into four subclasses based on their tertiary structures.5
The major target of the β-lactams are the HMW-PBPs as they are important for cell
survival. Class A HMW-PBPs catalyze the formation of the glycan chains (trans-glycosylation)
and both class A and class B PBPs catalyze the cross-linking of peptidoglycan stem-peptides
(transpeptidation) on the external side of the cytoplasmic membrane.5
The reduced toxicity and high specificity of peptidoglycan synthesis-inhibiting drugs to
humans also made β-lactams more preferable in bacterial inhibition as compared to other
antibiotics.5
Thus, there is a need for more research into finding non-β-lactams drugs that also display
high specificity for the target site, low toxicity to human cells, and are unhydrolysable by βlactamases.
Bacteria have succeeded over the years in developing various mechanisms to resist βlactams. These strategies or mechanisms include:
1. Production of β-lactamases, which catalyze the hydrolysis of the β-lactam rings in βlactams and subsequent transfer of plasmids, encoded with β-lactamases genes amongst
related and unrelated species. This is the most vital resistance mechanism in Gramnegative bacteria e.g. Neisseria gonorrhoeae and Haemophilus influenzae.6-9
2. Another important mechanism in Gram-positive bacteria is the production of low-affinity
PBPs which catalyze the transpeptidation reaction even in the presence of high
concentrations of β-lactam antibiotics. Most bacteria achieve this by mutations of
residues surrounding the active sites of the PBPs thus lowering the affinity of PBPs to β19

lactam. This is mostly observed in non-β-lactamase producing Gram-negative bacteria
and most Gram-positive bacteria (e.g. Streptococcus pneumoniae and MRSA).5,7,10
3. Target site accessibility also plays a key role in β-lactam drug action; the effectiveness of
β-lactams is dependent on their ability to cross the outer membrane and this is facilitated
by the outer membrane proteins (OMPs). However, bacteria further develop resistance to
β-lactam drugs by decreasing the production of such OMPs that facilitates the transport
of the β-lactams through the outer membrane of the cell, thus lowering their effectiveness
and increasing the minimum inhibitory concentration of such antibiotics. This is often
combined with another resistance mechanism such as β-lactamase expression.11,12
4. Decreasing the effective concentration of drugs in their periplasm is also exhibited by
Gram-negative bacteria through efflux pumps that facilitate the export of β-lactams
outside the cells.12

β-Lactamases
The β-lactamase enzyme was first identified and isolated by E. P. Abraham and E. Chain
from Bacillus (Escherichia) coli and they described it as B. coli “penicillinase”.13 This occurred
before the clinical use of penicillin. β-lactamases were not thought to be clinically relevant as of
that time since penicillin was targeted to treat staphylococcal and streptococcal infections, as
researchers then were unable to isolate the enzyme from these Gram-positive organisms. 13,14,15
Kirby et. al. successfully isolated these penicillinases from Staphylococcus aureus in 1944 and
this signaled the emergence of a major clinical problem as these enzymes would in some years
later become one of the leading causes of antibacterial resistance worldwide.16

20

The ever expanding number of β-lactam antibiotics has since increased the selective
pressure on bacteria, promoting the survival of organisms with multiple β-lactamases.17,18 Over
850 β-lactamases have been identified and it is speculated that high mutation frequency, rapid
recombination, and replication rates are responsible for bacteria being able to adapt to novel βlactams by evolution of these β-lactamases.19

Classification of β-lactamases
There are two major classification schemes that are used for categorizing β-lactamase
enzymes:
1. The Ambler Classes A through D, based on amino acid sequence homology, and
2. The Bush-Jacoby-Medeiros groups 1 through 4, based on substrate and inhibitor
profile.20,21
Classes A, C, and D serine-β-lactamase are known to share a lot of structural similarities
which make them hydrolyze β-lactams similarly. However, Class B β-lactamases are metallo-βlactamases (MBLs) and they possess either a single Zn2+ ion or a pair of Zn2+ ions coordinated to
His/Cys/Asp residues in the active site.22
The Ambler classification scheme has been used in this literature review.

Class A Serine β-lactamase
Generally, most class A enzymes are susceptible to the commercially available most β-lactamase
inhibitors like clavulanate, however, the K. pneumoniae carbapenemase (KPC) may be an
important exception to this generalization as they are resistant to clavulanate.23

21

Class A Extended-spectrum β-lactamases (ESBLs)
They are known to hydrolyze many of the oxyimino-cephalosporins, monobactam (aztreonam)
(but not cephamycins or carbapenems), and penicillin conferring resistance to bacteria that
possess them. This class is also well known to be inhibited by clavulanate.24,25

Class A Serine Carbapenemases
Class A serine carbapenemases include the nonmetallo carbapenemase of class A (NMC-A),
IMI, SME, and KPC. Carbapenems as well as cephalosporins, penicillins, and aztreonam can be
hydrolyzed by members of this group. This class of β-lactamases has been observed to occur in
Enterobacter cloacae, Serratia marcescens, and K. pneumoniae and are also susceptible to
clavulanate. 26

Class B Metallo-β-lactamases
These enzymes are Zn2+ dependent β-lactamases and they hydrolyze β-lactam antibiotics in with
a mechanism different from the other classes of β-lactamases (A, C, and D). They hydrolyze and
thus exhibit resistance to cephalosporins, carbapenems, penicillins, and the clinically available βlactamase inhibitors. An example is the New Delhi Metallo-β-lactamases 21,27

Class C Serine Cephalosporinase
Class C serine cephalosporinase accounts for an array of β-lactamase enzymes that are mostly
encoded in the bla gene of bacterial chromosomes. Organisms expressing this β-lactamase are
typically resistant to penicillins, β-lactam β-lactamase inhibitor combinations, and

22

cephalosporins, including cefoxitin, cefotetan, ceftriaxone, and cefotaxime. However, AmpC
enzymes are known to be inhibited by cloxacillin, oxacillin, and aztreonam.21,28

Class D Serine Oxacillinases
They were at first termed “oxacillinases” due to their ability to hydrolyze oxacillin at a rate of at
least 50%, in contrast to the relatively slow hydrolysis of oxacillin by classes A and C. They are
capable of conferring resistance to carbapenems, cephalosporins, and penicillins. 29

Evolution of β-lactam and non-β-lactam β-lactamase inhibitors
Due to the prevailing β-lactam resistance, the need for more effective inhibitors of βlactamases and bacterial growth has become more pertinent. The trend of antibiotic misuse and
overuse, including their utilization as growth promoters in animals, has further enhanced
bacterial resistance in recent times.30
Since 1970, various β-lactamase inhibitors (clavulanic acid, tazobactam, and sulbactam,
[Figure 2]) have been introduced into clinical medicine. They all possess a four-membered βlactam ring and are inactivators or “suicide inhibitors” of class A β-lactamases. They
significantly reduce MICs against various bacteria when combined with β-lactam-antibiotics.
Examples of such synergistic drug combinations include AugmentinTM (amoxicillin and
clavulanate), UnasynTM (ampicillin and sulbactam) and ZosynTM (piperacillin/tazobactam).
Notwithstanding the efficacy of these antibiotics, resistance was still observed after several years
of employing these combinational therapies for the treatment of bacterial infections. This
resistance was observed to be resulting from the production of inhibitor-resistant β-lactamases or
enzyme hyper production. During the last 40 years, numerous β-lactamase inhibitors, β-lactams,
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and non-β-lactams have been developed to try to curb this scourge (antimicrobial
resistance).6,31,32

Figure 2: β-lactam based β-lactamases inhibitors

Non-β-lactam Inhibitors
Aside the regular β-lactams based drugs and their derivatives, more scientists have
focused their attention on the synthesis and isolation of effective non-β-lactam based PBP
inhibitors which are also able to evade β-lactamase hydrolysis.
NXL104 (avibactam) (Figure 3) is a non-β-lactam that inhibits serine β-lactamases. In
combination with extended-spectrum cephalosporins and aztreonam, it is potent against Gramnegative infections (including Klebsiella).33–35 NXL104 has been the first β-lactamase inhibitor
to be studied in clinical trials since the introduction of tazobactam.36

Figure 3: Non β-lactam based β-lactamases inhibitors
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The non β-lactam based PBP inhibitors can be classified into three major groups:
1. Transition state analogs
2. Substrate analogs and
3. Non-covalent inhibitors

1.

Transition State Analog: Transition State Analog (TSA) inhibitors have been found to be

efficient serine β-lactamases and protease inhibitors.6,37,38 TSA inhibitors like boronic acid,
carbonyl compounds, and phosphonates have been identified as potent inhibitors of PBPs.
Boronic acid binds preferentially to the LMW-PBPs.5,39 Boronic acid compounds form
reversible, covalent bonds with serine proteases and inhibits these enzymes by assuming
tetrahedral reaction intermediates.40,41
Carbonyl compounds [peptide aldehydes Boc-L-Lys(Cbz)-D-Ala-H (Ki = 60 µM) and
Boc-L-Lys(Cbz)-L-Ala-H (Ki = 79 µM)] have also been identified as inhibitors of N. gonorrhoea
PBP3.42
Phosphonates are also known to be strong inhibitors of serine proteases which in some
ways are related to β-lactamase. The clinical potential of phosphonates has been limited by their
poor stability in aqueous solution and susceptibility to phosphodiesterases.6,43

2.

Substrate Analogs: Substrate analogs react as suicide substrates by acylation of the PBP

active serine, similarly to acylation by β-lactams.5 Bicyclic pyrazolidinones and the lactivicins
(LTV) have been shown to exhibit clinically relevant levels of antibacterial activities and PBP
inhibitors.44-46
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Bicyclic pyrazolidinones (Figure 4) compounds with strong electron withdrawing groups
in C3 positions were shown to have better in vitro activities compared to others.44

Figure 4: Bicyclic pyrazolidinones44

Lactivicin (LTV) (Figure 5) was the first natural PBP inhibitor without a β-lactam ring to
be isolated in 1986 from bacterial strains (Empedobacter lactamgenus and Lysobacter albus) by
the Takeda Research group.47-52
It possesses a unique ring structure comprising a functionalized L-cycloserinyl ring
linked to a γ-lactone ring. Its spectra of activity span a wide range of Gram-negative and Grampositive bacteria; however, its relatively strong toxicity was a setback. LTV derivatives have
been synthesized to increase its antibacterial activity against Gram-negative bacteria and
minimize its toxicity.45,47-52
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Figure 5: Lactivicin analogs45

3.

Non-covalent Inhibitors: Non-covalent inhibitors bind tightly to the active site of PBPs

without acylation, thus making them highly effective inhibitors. They do not require the
unfavorable conformational changes in the active site of PBP2a of MRSA that is required for
acylation.53,54 Examples of non-covalent inhibitors are arylalkylidene rhodanines, arylalkylidene
iminotriazolidenes (inhibitors of class C β-lactamases in the micromolar range),
aminothiadiazole and ortho-phenoxyldiphenylurea derivatives, naphthalene sulfonamides,
anthranilic acids, Cibacron Blue and Erie Yellow, cyclic peptides, and quinolones. 4-Quinolones
were found to be noncovalent inhibitors of PBPs of E. coli and B. subtilis however, all active 4quinolones had no in vitro antibacterial activities against E. coli or B. subtilis on their own.55-60

Pyrrolo[2,1-c][1,4]benzodiazepines (PBDS)
Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a group of natural products found in
actinomycetes commonly possessing a pyrrolo[1,4]benzodiazepine ring system. The first PBD to
be isolated and studied was Anthramycin from Streptomyces refuineus. It was first successfully
synthesized in a laboratory setting by Leimgruber et al. in 1965.61
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Figure 6: Examples of biologically active pyrrolobenzodiazepines

PBDs such as tomaymycin, anthramycin, and sibromycin (Figure 6) which have been
isolated and developed over the years exert potent antibacterial activity against human pathogens
through their ability to bind to DNA. This is done through the formation of covalent bond
through their N10-C11 imine/carbinolamine moieties to the C2-amino position of a guanine
residue within the minor groove of DNA (Figure 7). Monomers of PBDs (e.g. Anthramycin)
span three DNA base pairs with a preference for Pu-G-Pu (where Pu = purine and G = guanine;
reactive guanine emboldened) sequences and block transcription through RNA polymerase
inhibition.61-64
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Figure 7: Mechanism of PBD binding to the N2 of guanine in the DNA minor groove.
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Tethering of two PBD units through an inert propyldioxy [-O-(CH2)3-O-diether] or
pentyldioxy [-O-(CH2)5-O-diether] linker via their C8/C8′ positions to form dimers (e.g. ELB21) has also been shown to enhance potency, binding affinity, and sequence specificity of PBDs.
These dimers are capable of cross-linking appropriately separated guanines on opposing DNA
strands.65
High degree of cytotoxicity over the years have, however, rendered PBDs unattractive as
antibacterial antibiotics when compared to other classes of antimicrobial compounds even if
some PBDs have potentials as cancer chemotherapeutics. Notwithstanding, increasing evolution
of multidrug-resistant pathogens capable of a rapid and efficient horizontal transmission of genes
encoding antibiotic resistance determinants has led to the erosion of most of the front-line
antibacterial chemotherapeutic agents of therapeutic value in a relatively short time frame. This
has led to the reconsideration of PBDs and other possibly cytotoxic antibiotics as possible lead
compounds for the production of better antibacterial agents by many research groups.66,67 More
recently, Colistin, a polymyxin antibiotic which was deemed too toxic for non-topical use is now
widely used systemically due to the limited therapeutic options available for these infections.68
ELB-21 (Figure 8) is a pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer that shows potent
in vitro bactericidal activity against a wide range of Gram-positive clinical isolates, including
methicillin-resistant strains of Staphylococcus aureus (MRSA) and vancomycin-resistant
enterococci (VRE).69
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Figure 8: Structure of the pyrrolobenzodiazepine dimer ELB-21

Justification of Research
One of the major reason for trying to exploit PBDs as possible β-lactamase inhibitors
stemmed from the fact that PBDs have regions in their structure that are similar to the active
region of regular β-lactam β-lactamase inhibitors. In theory, by breaking a bond in regular βlactam β-lactamase inhibitors, we could arrive at PBD analogs that bear the same sites of activity
as regular β-lactam β-lactamase inhibitors as shown in Figure 9 below. Thus, our aim was to
make PBD analogs which retained that activity units/regions and to evaluate them as possible
non-β-lactam β-lactamase inhibitors. Secondly, the attack on the carbonyl carbon initiated by the
Ser-OH of the active sites of Ser β-lactamases could possibly lead to the formation of a very
stable covalent bond that could lead to the PBDs being suicide inhibitors of the β-lactamases.
Figure 10 shows the mode of action of clavulanic acid (a classic β-lactam β-lactamase inhibitor)
in relation to the possible mechanism of action in Figure 11.
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Figure 9: The structure-based relationship between β-lactam β-lactamase inhibitors and PBDs.
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Figure 10: Mechanism of action of β-lactam β-lactamase inhibitors (suicide inhibitors) (Adapted
from http://wizard.pharm.wayne.edu/medchem/betalactam.html).

Figure 11: Proposed mechanism of action of PBD derivatives as β-lactamase inhibitors

PBD-dilactam (1) is a natural product from Isatis indigotica and can also be easily
synthesized in the laboratory. The capability of natural product 1 and its synthetic analogs (e.g.
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2-6) to interact with the DNA of bacterial cells is linked to their ability to cross the outer
membrane of microorganisms thus making them promising candidates for new non-β-lactam βlactamase inhibitors.70-72 PBD dilactam (1) is a natural product from Isatis indigotica and can
also be easily synthesized in the laboratory.72

Figure 12: Examples of Pyrrolo[2,1-c][1,4]benzodiazepines derivatives synthesized during
research.

Still in line with making further derivatives of PBDs that will serve as inhibitors of βlactamase, we also made some smaller derivatives using N-phenylacetamide as our starting
material. N-phenylacetamide derivatives have been known to have numerous biological
activities ranging from antileishmanial73, analgesic74, antipyretic75-77, antiviral78, anti-parasitic,79
and antibacterial activities (antitubercular80) to anticancer81 properties depending on the
derivation. By taking a cue from the justification of PBDs mentioned above, N-phenylacetamide
can be also modified to form active regions that could possibly interact with the active site of βlactamases, in the same manner, we suggested for PBDs. Thus, we also attempted to make Nphenylacetamide derivatives some of which are shown in Figure 14 below to also be evaluated as
potential non β-lactam β-lactamase inhibitors.
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Another reason for the synthesis of the N-phenylacetamide derivatives was to reduce the
size of the PBD structure while keeping the suspected active region to increase its availability to
the active site of the enzyme. In PBDs, proper interaction or binding to the active site appears to
be hindered due to the seeming bulkiness of the PBDs.
In addition to the above-mentioned reasons, oxadiazoles have recently been discovered to
inhibit PBPs (a close relative of β-lactamases) in MRSA. A good example of such oxadiazole is
5-(4-fluorophenyl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (Figure 13). It
has been shown to inhibit PBP2a with IC50 of 8 µg/mL.82

Figure 13: 5-(4-fluorophenyl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole82

This implies that there is a high possibility of the oxadiazoles (6, 7, 12 and 13) that we
intended to make during the course of this study stood a high chance of being inhibitory to βlactamases.

Figure 14: N-phenylacetamide derivatives made during this research work
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Specific Aims
In this research, we aimed to study the molecular interaction of PBD derivatives and the
active site residues of TEM-1 β-lactamase using the docking software Sanjeevini ParDOCK.83
After molecular docking, derivatives that exhibited promising attributes of being efficient
inhibitors were synthesized using PBD-dilactam (1) and N-phenylacetamide as the starting
materials. Enzyme inhibition kinetics studies using the TEM-1 and P99 β-lactamase was done
using Nitrocefin as the substrate to ascertain the efficacy of synthesized PBD and Nphenylacetamide derivatives as β-lactamase inhibitors. Clavulanic acid was used as the positive
control in both molecular modeling and enzyme inhibition kinetics.
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CHAPTER 2
EXPERIMENTAL SECTION (MATERIALS AND METHODS)
Prediction of Drug-likeness of PBD derivatives
All PBD derivatives synthesized during this work were first subjected to the Lipinski’s
rule of 5 which helps to distinguish between a drug-like and a non-drug-like compound. It is
used to predict the high probability of success or failure of a compound as a drug due to its druglikeness.84 This rule as named was formulated by Christopher A. Lipinski in 1997 based on the
fact that most drugs that are administered orally are moderately lipophilic and relatively small
molecules. 84,85
The Lipinski’s rule of 5 evaluates if a chemical compound with certain biological or
pharmacological activity has properties that would most likely make it an orally active drug in
humans. Molecular properties of compounds described by the rule include their absorption,
distribution, metabolism, and excretion in the human body. However, as important as the
Lipinski’s rule of 5 is in its determination of drug-likeness, it doesn’t predict if a compound
would be pharmacologically active.85,86
To qualify for a high probability of success, molecules have to comply with 2 or more of
the Lipinski’s rules. They must possess less than 5 hydrogen bond donors and less than 10
hydrogen bond acceptors, have a molecular mass less than 500 Dalton, possess molar refractivity
between 40–130, and have a high lipophilicity (expressed as LogP less than 5). 84-86
The Lipinski’s rule of 5 parameters for all compounds was calculated using the
Sanjeevini Drug Design Software by SCFBio, India.
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Molecular Docking using ParDOCK
ParDOCK by Sanjeevini Supercomputer Facility, India is an all-atom energy based
Monte Carlo docking procedure tested on a dataset of 226 protein-ligand complexes.83
The structural inputs for ParDOCK are a reference complex (target protein bound to a
reference ligand) and a candidate molecule. The ParDOCK protocol consists of four main steps:
(a) identification of the best possible grid/translational points in a radius of 3 Å around the
reference point (center of mass);
(b) generation of protein grid and preparation of energy grid in and around the active site of the
protein to pre-calculate the energy of each atom in the candidate ligand;
(c) Monte Carlo docking and intensive configurational search of the ligand inside the active site;
(d) identification of the best-docked structures based on an energy criterion and prediction of the
binding free energy of the complex.83
Figure 15 shows the flowchart of docking methodology adopted in ParDOCK.
ParDOCK is a docking software that was developed for the purpose of finding the
binding mode of the ligand to its receptor to a known binding site and not for the purpose of
predicting all possible binding sites. The reference complex, therefore, helps in initiating the
search. For the sake of efficiency, a portion of the receptor enclosing the binding site is
considered and this simplification is accounted for in atomic level energy calculations.
ParDOCK, a Monte Carlo based docking protocol was used because it is able to reproduce the
crystal conformation to an average root-mean-square deviation (RMSD) of 0.53 in 98% of the
cases.83
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Figure 15: A computational flowchart for docking methodology (Adapted from Gupta, et al.
Protein and Peptide Letters, 2007, 14, 7, 632-646)83
Docking studies of PBD derivatives were performed using this software. Crystal structure
of TEM-1 (PDB ID: 1LI0) was downloaded from Research Collaboratory for Structural
Bioinformatics (RCSB) Protein Data Bank. All the structures of PBD derivatives were prepared
by using Accelrys Discovery Studio Visualizer 4.5 from Biovia and saved in protein data bank
(pdb) file format before used in docking procedure.
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Syntheses of PBD Derivatives
Materials
Starting materials isatoic anhydride, L-proline and N-phenylacetamide were purchased
from Alfa Aesar Chemical company. Deuterated solvents (CDCl3-d and DMSO-d6) were
obtained from Sigma-Aldrich Chemical Company. Solvents (dichloromethane DCM, absolute
ethanol, 95% ethanol, ethyl acetate, hexane, diisopropyl ether, diethyl ether, chloroform, acetone,
dimethylformamide (DMF), methanol, toluene, propylamine, nitromethane, 2-propanol,
anhydrous tetrahydrofuran (THF), anhydrous dioxane), salts (MgSO4, Na2S2O3, NaHCO3,
K2CO3 Na2SO4, NaCl, HgCl2, hydroxylamine hydrochloride [NH2OH·HCl], MOPS buffer) and
other reagents (Lawesson’s reagent, 1,1 carbonyl diimidazole (CDI), 1,1 thionyl diimidazole
(TDI), ammonia gas, polyphosphoric acid (PPA), ammonium hydroxide (NH3 aq), nitroethane,
aniline) were purchased from Alfa Aesar Chemical Company. Nitrocefin (NCF) and bovine
serum albumin (BSA) used for enzyme kinetics assay were purchased from BioVision
Incorporated. Enzymes TEM-1 β lactamase and P99 β lactamase were purchased from Invitrogen
and Sigma-Aldrich Chemical Company, respectively.

Instrumentation
A Shimadzu IR Prestige-21 FTIR spectrometer was used for Infra-Red studies and a Jeol
400 MHz Nuclear Magnetic Resonance Spectrometer was used for 1H NMR and 13C NMR. An
Agilent Technologies Cary 8454 UV/Vis spectrometer with a PCB 1500 water Peltier system by
Agilent Technologies and quartz 1000 µL cuvettes with a path length of 1 cm were used for
UV/Vis Absorbance and kinetic studies. Melting point was determined using a Thermo Scientific
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Electrothermal Digital Melting Point Apparatus IA9100 series and molecular weight
determination was done using a Shimadzu GC-MS – QP 2010 Plus.
The 1H and 13C NMR spectra were recorded in DMSO-d6 and CHCl3-d on a JEOL
Eclipse 400 MHz NMR Spectrometer operating at 400 MHz for 1H and 100 MHz for 13C NMR.
Chemical shift (δ) values are expressed in parts per million (ppm) and are referenced to the
residual solvent signals of DMSO-d6 and CDCl3-d at δH/δC 2.50/39.5 and 7.25/76.8 ppm, 77.1
ppm, and 77.4 ppm respectively. Optical rotations were measured with a JASCO DIP-310 digital
polarimeter.

Chemistry

General procedure for the preparation of the (S)-1,2,3,11a-tetrahydro-5Hbenzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H)-dione (1): In a 250 mL one-neck round bottom
flask, a suspension of isatoic anhydride (20.0 g, 122.68 mmol) and L-proline (14.12 g, 122.6
mmol) in DMF (60 mL) was heated to 155 ˚C for 5 h. The solvent was removed in vacuo and the
residue was taken up in cold water. The precipitate was collected and dried to give the dilactam.
The resultant solid was purified by recrystallization through slow evaporation in acetone/DMF
(10:1) to afford pure colorless crystals in very good yield.
Yield: 24.78 g (93.6 %). m.p.: 223 – 225 °C. 
= + 512 º (c = 0.5, CH3OH).

1

H-NMR (400 MHz, DMSO-d6): δ = 1.76–2.00 (m, 4H), 3.42–3.48 (m, 1H), 3.56–3.61 (m, 1H),

4.10 (d, 1H), 7.11–7.13 (dd, 1H), 7.20–7.24 (m, 1H), 7.49–7.51 (m, 1H), 7.77–7.79 (dd, 1H),
10.51 (s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6): δ = 23.6, 26.3, 40.4, 56.7, 121.8, 124.4,
127.1, 130.8, 132.6, 136.9, 165.0 (CO), 171.3 (CO). IR (KBr): ν̃ (cm-1) = 3222 (NH), 3206,
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2955, 2918, 2850, 1691 (CO), 1680 (CO), 1621, 1551, 1536, 1479, 1443, 1412, 1385, 1285,
1259, 1179, 759, 701, 615. UV λmax (MeOH): 198, 274 nm. GC-MS (70 eV) m/z (%): 216 (10)
[M+], 119 (14), 92 (20), 70 (100), 64 (10).

General procedure for the preparation of (S)-11-thioxo-1,2,3,10,11,11a-hexahydro-5Hbenzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (2): In a 250 mL one neck round bottom flask, a
mixture of dilactam (2.15 g, 10 mmol) and Lawesson’s reagent (4.04 g, 10 mmol) in THF (100
mL) was stirred for 24 h at room temperature. Evaporation of solvent in vacuo gave a yellow
solid residue which was purified by dissolving in toluene and filtered off by gravity. The solid
was further washed with cold toluene to obtain pure yellow solid. Recrystallization through slow
evaporation in acetone/DMF (20:1) to afford pure yellowish crystals in very good yield.
Yield: 2.03 g (88.0%). m.p.: 272-274 oC. 
= + 762 º (c = 0.5, CHCl3)

1

H-NMR (400 MHz, DMSO-d6): δ = 1.98-1.83 (m, 1H), 1.98–2.15(m, 2H), 2.88 (d, J=5.9 Hz,

1H), 3.42–3.48 (m, 3H), 3.56–3.61 (m, 1H), 4.28 (d, J=6.2 Hz, 1H), 7.27–7.29 (dd, J=8.1 Hz,
1H), 7.33–7.37 (m, 1H), 7.55–7.60 (ddd, J=7.7, 1.2 Hz, 1H), 7.82–7.84 (dd, J=7.7, 1.5 Hz, 1H),
8.13 (s, 1H, NH). 13C-NMR (100 MHz, DMSO-d6): δ = 23.2, 29.5, 47.4, 60.3, 122.3, 126.2,
128.3, 130.8, 132.7, 137.0, 164.7 (CO), 202.5 (CS). IR (KBr): ν̃ (cm-1) = 3125 (N-H), 3094,
3063, 3024, 2974, 1620 (C=O), 1579, 1523, 1478, 1452, 1418, 1381, 1272, 1193, 1166, 1145,
1103, 1069, 1055, 887, 833, 817, 786, 755, 695, 664, 625. UV λmax (MeOH): 194, 274 nm. GCMS (70 eV) m/z (%): 232 (7) [M+], 108 (6), 70 (100), 68 (6).
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General procedure for the preparation of (S)-11-(propylamino)-1,2,3,11a-tetrahydro-5Hbenzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (3): To a stirred suspension of monothiolactam (5.78
g, 25.0 mmol) and propylamine (20 mL) was added HgCl2 (7.14 g, 26.25 mmol) at 60 ˚C. The
mixture was stirred for a further 1 h at this temperature. After cooling to room temperature, the
mixture was filtered through a plug of celite and eluted with CH2Cl2. The filtrate was washed
with sat. Na2S2O3(aq) and after extraction with CH2Cl2, the combined organic layer was dried
over MgSO4, filtered, and the solvent and excess amine were evaporated under reduced pressure.
The resultant solid was purified by recrystallization in nitromethane to afford pure colorless
crystals in very good yield.
Yield: 5.64 g (88%). m.p.: 159-161 oC.  = + 1106 º (c = 0.5, CHCl3)


1

H-NMR (400 MHz, CDCl3-d6): δ = 0.96–0.99 (t, J=7.5 Hz, 3H), 1.64-1.69 (m, 2H), 1.99-2.12

(m, 2H), 2.20-2.25 (m, 2H), 3.37-3.38 (d, J=4.8 Hz, 2H), 3.50-3.60 (m, 1H), 3.84-3.88 (m, 1H),
4.01-4.03 (t, J=4.9 Hz, 1H), 4.68 (s, 1H), 7.03–7.05 (m, 1H), 7.07–7.11 (m, 1H), 7.36–7.38 (ddd,
J=8.6, 6.8, 1.3 Hz,1H), 7.91–7.93 (dd, J=7.7, 1.5 Hz, 1H). 13C-NMR (400 MHz, CDCl3): δ =
11.7, 22.3, 23.9, 26.8, 43.3, 46.5, 54.4, 122.2, 126.5, 126.9, 130.1, 131.6, 146.7, 156.2 (CN),
166.8 (CO). IR (KBr): ν̃ (cm-1) = 3851, 3798, 3745, 3356 (N-H), 3319 (N-H), 3287, 3061, 2941,
2880, 2815, 2359, 2328, 1826, 1791, 1731, 1605 (C=O), 1554, 1531, 1506, 1456, 1406, 1383,
1336, 1256, 1215, 1150, 1096, 1067, 1035, 991, 918, 835, 761, 703, 635. UV λmax (MeOH): 198,
273 nm. GC-MS (70 eV) m/z (%): 257 (21) [M+], 146 (23), 119 (23), 90 (21), 70 (100).

Synthesis of (14aS)-3-phenyl-1-propyl-1,12,13,14,14a,14b-hexahydro-2H,10Hbenzo[e]pyrimido[2,1-c]pyrrolo[1,2-a][1,4]diazepine-2,4,10(3H)-trione (4): A mixture of 3 (1
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mmol, 0.257 g) and bis(2,4,6-trichlorophenyl) 2-phenylmalonate (1 mmol, 0.539 g) was heated
at 190 ºC for 10 minutes in a Zincke apparatus under high vacuum. The residue was treated with
diethyl ether to give a dark brown precipitate which was collected by filtration and washed with
diethyl ether. Recrystallization was done in DMF/Water, 95% ethanol and 2-propanol.
Yield: 300 mg (75 %) m.p.: 230 – 233 °C. 
= 0 º (c = 0.5, CHCl3)

1

H-NMR (400 MHz, CDCl3): δ = 0.77–0.81 (t, J=7.3 Hz, 3H), 1.31–1.39 (m, 2H), 2.04–2.17 (m,

1H), 2.21–2.28 (m, 1H), 2.62–2.71 (m, 1H), 2.77–2.82 (dd, J=14.6, 6.2 Hz, 1H), 2.96–3.03 (m,
1H), 3.96–4.11 (m, 2H), 4.17–4.25 (m, 1H), 4.71 (s, 1H), 7.28–7.30 (m, 2H), 7.36–7.45 (m, 5H),
7.54–7.59 (td, J=7.8, 1.6 Hz, 1H), 8.02–8.04 (m, 1H). 13C-NMR (100 MHz, CDCl3): δ = 11.2,
20.6, 21.5, 29.6, 48.4, 49.5, 59.1, 118.0, 125.5, 127.5, 128.2, 128.4, 130.8, 131.3, 132.3, 133.3
(CO), 139.8 (CO), 167 (CO). IR (KBr): ν̃ (cm-1) = 2957, 2918, 2860, 2355, 1958, 1728, 1683
(C=O), 1633 (C=O), 1576, 1487, 1453, 1352, 1297, 1252, 1221, 1185, 1150, 899, 800, 753, 719,
698, 665, 631. UV λmax (AcO): 194, 274 nm. GC-MS (70 eV) m/z (%): 401 (66) [M+], 215 (11),
187 (29), 118 (100), 90 (46).

General procedure for the preparation of (S)-11-(hydroxyamino)-1,2,3,11a-tetrahydro5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (5): Hydroxylamine hydrochloride (800 mg,
11.51 mmol) and potassium carbonate (6 g, 43.5 mmol) was added to a solution of
monothiolactam (1.74 g, 7.5 mmol) in absolute ethanol (40 mL) and stirred for 48 hours at room
temperature. The initial yellow mixture decolorized and H2S was released. The mixture was
taken up in dichloromethane (120 mL) and washed with water (80 mL). The organic layer was
further washed with brine and dried over Na2SO4. The solvent was removed in vacuo. The crude
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residue was dissolved in a mixture of diethyl ether/hexane (1:1), filtered and further washed in
20 mL of the solvent mixture to obtain 1.63 g (94% yield) of the pure solid. Recrystallization
was done in nitromethane to yield off-white crystals.
Yield: 1.63 g (94%). m.p.: 150 – 153 °C.  = + 488 º (c = 0.5, CDCl3)


1

H-NMR (400 MHz, DMSO-d6): δ = 1.86–2.03 (m, 3H), 2.56–2.60 (m, 1H), 3.47–3.61 (m, 4H),

4.31–4.33 (m, 1H), 7.03–7.06 (t, J=7.5 Hz, 1H), 7.25–7.27 (dd, J=16.8, 7.7 Hz, 1H), 7.37–7.41
(t, J=7.7 Hz, 1H), 7.66–7.68 (d, J=7.7 Hz, 1H), 8.75 (s, 1H, N-H), 10.08 (s, 1H, OH). 13C-NMR
(100 MHz, CDCl3-d6): δ = 23.4, 25.9, 47.4, 54.4, 120.5, 123.5, 125.8, 131.6, 132.6, 136.9, 151.2,
166.2 (CO). IR (KBr): ν̃ (cm-1) = 3788, 3716, 3281, 2965, 2911, 2878, 2806, 2351, 1724, 1689,
1658, 1612, 1573, 1552, 1530, 1480, 1453, 1425, 1396, 1273, 1227, 1201, 1162, 1108, 1040,
997, 957, 933, 884, 847, 807, 787, 756, 701, 663. UV λmax (MeOH): 198, 313 nm. GC-MS (70
eV) m/z (%): 231 (20) [M+], 144 (37), 90 (35), 70 (100).

Synthesis of (S)-11,12,13,13a-tetrahydro-3H,9H-benzo[e][1,2,4]oxadiazolo[3,4c]pyrrolo[1,2-a][1,4]diazepine-3,9-dione (6): In a nitrogen atmosphere, 5 (231 mg, 1 mmol)
dissolved in anhydrous dioxane (8 mL) was added to 1,1 carbonyl diimidazole (486.45 mg, 3.3
mmol). The reaction mixture was refluxed for 12 hours and the solvent removed in vacuo
afterward. The residue was taken up in dichloromethane and washed three times with water. The
organic layer was dried over Na2SO4 and the solvent removed in vacuo. The crude residue was
purified by flash column chromatography to obtain a white solid which was recrystallized to get
crystals used for x-ray crystallography.
Yield: 226.16 mg (88 %). m.p.: 180 – 182 °C.  = + 142 º (c = 0.5, CDCl3)
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1

H-NMR (400 MHz, CDCl3-d6): δ = 1.58 (d, J=12.1 Hz, 2H), 2.10-2.23 (m, 2H), 2.30-2.39 (m,

1H), 2.82-2.87 (tt, J=9.9, 3.4 Hz, 1H), 3.67-3.74 (m, 1H), 3.90-3.95 (m, 1H), 4.58-4.61 (dd,
J=8.4, 2.9 Hz, 1H), 7.49–7.53 (m, 1H), 7.64–7.68 (td, J=7.8, 1.6 Hz, 1H), 7.83-7.85 (d, J=7.3 Hz,
1H), 8.02–8.04 (dd, J=7.9, 1.6 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ = 23.4, 25.6, 47.9, 51.2,
122.4, 128.6, 128.6, 128.7, 132.8, 156.3 (CN), 158.0 (CO), 164.2 (CO). IR (KBr): ν̃ (cm-1) =
3623, 3335, 3044, 2956, 2918, 2875, 2851, 2381, 2349, 2296, 2199, 2105, 1981, 1838, 1787,
1728, 1710, 1690, 1657, 1640, 1599, 1551, 1468, 1451, 1410, 1301, 1267, 1167, 1081, 1025,
990, 761, 702, 662, 608. UV λmax (MeOH): 198, 274 nm. GC-MS (70 eV) m/z (%): 257 (22)
[M+], 144 (100),116 (38), 90 (33), 44 (33), 41 (24).

X-ray crystallography study of 6: A large colorless prism was cut (0.10 x 0.15 x 0.23
mm3) and centered on the goniometer of a Rigaku Oxford Diffraction Gemini E diffractometer
operating with MoKα radiation. The data collection routine, unit cell refinement, and data
processing were carried out with the program CrysAlisPro.87 The Laue symmetry and systematic
absences were consistent with the monoclinic space groups I2 and I2/m. As the sample was
known to be enantiomerically pure, the acentric space group, I2, was chosen to give Z=4 and
Z’=1. The absolute configuration could not be determined from the anomalous dispersion
effects. The structure was solved using SHELXS-201488 and refined using SHELXL-2014 via
Olex2.89 The final refinement model involved anisotropic displacement parameters for nonhydrogen atoms and a riding model for all hydrogen atoms.

Synthesis of (S)-3-thioxo-11,12,13,13a-tetrahydro-3H,9H-benzo[e][1,2,4]oxadiazolo[3,4c]pyrrolo[1,2-a][1,4]diazepin-9-one (7): In a nitrogen atmosphere, 5 (231 mg, 1 mmol) dissolved
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in anhydrous dioxane (8 mL) was added to 1,1 thionyl diimidazole (486.45 mg, 3.3 mmol). The
reaction mixture was refluxed for 12 hours and the solvent removed in vacuo afterward. The
residue was taken up in dichloromethane and washed three times with water. The organic layer
was dried over Na2SO4 and the solvent removed in vacuo. The crude residue was purified by
flash column chromatography to obtain a pale yellow solid. This was recrystallized using
Hexane: Ethyl acetate 1:1
Yield: 245.7 mg (90 %). m.p.: 216 – 218 °C. 
= + 34 º (c = 0.5, CDCl3).

1

H-NMR (400 MHz, CDCl3): δ = 1.17–1.27 (m, 1H), 2.06–2.29 (m, 2H), 2.32–2.47 (m, 1H),

2.84–2.90 (m, 1H), 2.88 (tt, J=9.9, 3.3 Hz, 1H), 3.65–3.72 (m, 1H), 3.90–3.95 (m, 1H), 4.57–
4.60 (dd, J = 8.6, 2.7 Hz, 1H), 7.55–7.59 (td, J=7.6, 0.9 Hz, 1H), 7.67–7.72 (m, 1H), 8.01–8.04
(dd, J=8.1, 1.5 Hz, 1H), 8.27–8.29 (dd, J=8.2, 0.9 Hz, 1H). 13C-NMR (100 MHz, CDCl3): δ =
23.5, 26.5, 47.6, 51.0, 124.7, 129.8, 131.8, 132.2. IR (KBr): ν̃ (cm-1) = 3788, 3716, 3281, 2965,
2911, 2878, 2806, 2351, 1724, 1689, 1658, 1612, 1573, 1552, 1530, 1480, 1453, 1425, 1396,
1273, 1227, 1201, 1162, 1108, 1040, 997, 957, 933, 884, 847, 807, 787, 756, 701, 663. UV λmax
(MeOH): 198, 276 nm. GC-MS (70 eV) m/z (%): 273 (70) [M+], 146 (42), 102 (75), 90 (65), 69
(44), 43 (100).

General procedure for the preparation of N-phenylethanethioamide (8): In a 250 mL oneneck round bottom flask, a mixture of 0.5 M solution of acetanilide (6.75 g, 50 mmol) in
dichloromethane (DCM) (100 mL) and 0.25 M Lawesson’s reagent (10.1 g, 25 mmol) in DCM
(100 mL) was stirred for 5 hours at room temperature. Evaporation of solvent in vacuo gave a
yellow solid residue which was purified by column chromatography using DCM.
Yield: 7.02 g (93 %). m.p.: 74 - 76 °C. 
= 0 º (c = 0.5, CDCl3)
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1

H-NMR (400 MHz, CDCl3): δ = 2.16 (s, 3H), 7.08–7.11 (t, 1H), 7.28–7.32 (t, 2H), 7.48–7.50

(d, J=7.7 Hz, 1H), 13C-NMR (100 MHz, CDCl3): δ = 24.7, 120, 124.4, 129.1, 139, 169.6 (CO),
IR (KBr): ν̃ (cm-1) = 3184, 3164, 3002, 2957, 2920, 2359, 1595, 1533, 1495, UV λmax (MeOH):
198, 277 nm
GC-MS (70 eV) m/z (%): 151 (43) [M+], 110 (54), 93 (100), 77 (100), 59 (76).

Synthesis of (E)-N'-phenyl-N-propylacetimidamide (9): To a stirred suspension of 8 (755
mg, 5 mmol) and propylamine (20 ml, 59.11 mmol) was added HgCl2 (1.42 g, 5.25 mmol) at 60
˚C. The mixture was stirred for a further 1 hour at this temperature. After cooling to room
temperature, the mixture was filtered through a plug of celite and eluted with CH2Cl2. The
filtrate was washed with sat. Na2S2O3(aq) and after extraction with CH2Cl2, the combined
organic layer was dried over MgSO4, filtered, and the solvent and excess amine were evaporated
under reduced pressure. The resultant solid was purified by fractional distillation to yield a
brownish liquid which solidifies on refrigeration.
Yield: 619.5 mg (70 %). m.p.: 180 - 182 °C. 
= 0 º (c = 0.5, CDCl3)

1

H-NMR (400 MHz, CDCl3): δ = 0.96–1.00 (m, 3H), 1.19 (s, 1H), 1.57–1.66 (m, 2H), 1.77 (s,

3H), 3.28–3.32 (t, J=4.4 Hz, 2H), 6.75–6.77 (m, 2H), 6.94–6.97 (d, J=6.6 Hz,1H), 7.21–7.29 (m,
2H). 13C-NMR (100 MHz, CDCl3): δ = 14.3, 21.5, 30.4, 60.5, 122.6, 128.8, 131, 171.3, 207.2.
IR (KBr): ν̃ (cm-1) = 3419, 3282 (NH), 2961, 2929, 2872, 2362, 1626, 1592, 1542, 1487, 1382,
1261, 1223, 1168, 1070, 900, 800, 743, 699. UV λmax (MeOH): 194, 274 nm. GC-MS (70 eV)
m/z (%): 176 (19) [M+], 133 (16), 118 (73), 93 (96), 77 (100), 59 (30), 42 (56).
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Synthesis of 2-methyl-1,5-diphenyl-3-propyldihydropyrimidine-4,6(1H,5H)-dione (10):
A mixture of 9 (1 mmol, 176 mg) and bis(2,4,6-trichlorophenyl) 2-phenylmalonate (1 mmol,
0.539 g) was heated at 100 ºC for 10 minutes in a Zincke apparatus under high vacuum. The
residue was treated with diethyl ether to give a dark brown precipitate which was collected by
filtration and washed with diethyl ether. Recrystallization was done in DMF/water, 95% ethanol
and 2-propanol.
Yield: 194 mg (60 %). m.p.: 257–259 °C. 
= 0 º (c = 0.5, CDCl3)

1

H-NMR (400 MHz, CDCl3): δ = 1.03–1.06 (m, 3H), 1.59 (s, 1H), 1.78–1.87 (m, 2H), 2.41 (d,

J=4.4 Hz, 2H), 4.08–4.12 (m, 2H), 7.12–7.15 (m, 1H), 7.22–7.27 (m, 2H), 7.27–7.31 (m, 1H),
7.48–7.52 (m, 2H), 7.52–7.57 (m, 2H), 7.77–7.79 (dd, J=8.4, 1.1 Hz, 2H). 13C-NMR (100 MHz,
CDCl3): δ = 24.7, 120, 124.4, 129.1, 139, 169.6 (CO). IR (KBr): ν̃ (cm-1) = 2962, 2930, 2875,
2362, 2341, 1643 (CO), 1595, 1549, 1482, 1442, 1379, 1338, 1274, 1158, 988, 775, 752, 696,
678, 620. UV λmax (MeOH): 198, 273 nm. GC-MS (70 eV) m/z (%): 321 (15) [M+], 277 (15),
249 (14), 145 (19), 118 (20), 90 (100), 77 (35), 41 (27).

Synthesis of (E)-N-hydroxy-N'-phenylacetimidamide (11): Hydroxylamine hydrochloride
(1.05 mg, 15 mmol) and sodium carbonate (1.5 g, 10 mmol) was added to a solution of 8 (1.5 g,
10 mmol) in dioxane (40 mL) and stirred for 48 hours at 50 ºC. The initial yellow mixture
decolorized and H2S was released. The mixture was taken up in DCM (30 mL) and washed with
water twice (40 mL). The organic layer was dried over Na2SO4. The solvent was removed in
vacuo. The crude residue was purified using column chromatography using a solvent mixture of
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ethyl acetate /hexane (4:1). The white product collected after evaporation of the solvent was then
recrystallized from water to give white crystals.

An alternative synthesis of 11: A mixture of nitroethane (12.5 mmol) and aniline (10
mmol) in PPA (20 g, 86 % P2O5) was vigorously stirred. The reaction mixture was heated for 5
hours at 110 ºC. The mixture was cooled down to 80 ºC and diluted with water (50 mL) after
TLC confirmed total consumption of starting material. 20 % aqueous ammonia was used to
neutralize the mixture (to pH ̴ 9), heated to reflux, and filtered. The filtrate was cooled down to 0
ºC, to form a crystalline precipitate which was collected by suction filtration recrystallized from
water.
= 0 º (c = 0.5, CDCl3)
Yield: a. 825 mg (55 %). b. 1.17 g (78 %) m.p.: 120 °C. 

1

H-NMR (400 MHz, CDCl3): δ = 1.97 (s, 3H), 7.06–7.07 (dd, J=8.4, 1.1 Hz, 2H), 7.12–7.15 (m,

1H), 7.29-7.34 (m, 2H). 13C-NMR (100 MHz, CDCl3): δ =16.1, 123.9, 124.7, 129.3, 139.0,
150.7 (CO). IR (KBr): ν̃ (cm-1) = 3435, 3182, 3091 (OH), 2999, 2878, 2813, 1611, 1465, 1411,
1343, 758. UV λmax (MeOH): 198, 245 nm. GC-MS (70 eV) m/z (%): 150 (15) [M+], 133 (33),
118 (30), 93 (100), 77 (74), 65 (35), 51 (24).

Synthesis of 3-methyl-4-phenyl-1,2,4-oxadiazol-5(4H)-one (12): In a nitrogen
atmosphere, 11 (150 mg, 1 mmol) dissolved in anhydrous dioxane (10 mL) was added to CDI
(535.1 mg, 3.3 mmol). The reaction mixture was stirred at 50 °C for 24 hours and the solvent
removed in vacuo afterward. The residue was taken up in DCM and washed three times with
water. The organic layer was dried over Na2SO4 and the solvent removed in vacuo. The crude
residue was purified by flash column chromatography to obtain a white solid, 106 mg (60 %).
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The solid was further purified by recrystallization using hexane and ethyl acetate to obtain white
crystals.
Yield: 106 mg (60 %). m.p.: 133–135 °C. 
= 0 º (c = 0.5, CDCl3)

1

H-NMR (400 MHz, CDCl3): δ = 2.19 (s, 3H), 7.30–7.32 (d, J=2.9 Hz, 1H), 7.51-7.54 (m, 2H),

7.55–7.56 (m, 1H). 13C-NMR (100 MHz, CDCl3): δ = 11.3, 126.8, 130.1, 130.2, 131.2, 156.2
(CO). IR (KBr): ν̃ (cm-1) = 3062, 2926, 1766, 1595, 1502, 1445, 1420, 1310, 1168, 1080, 1004,
885, 756, 692, 623. UV λmax (MeOH): 197, 274 nm. GC-MS (70 eV) m/z (%): 176 (34) [M+],
131 (54), 91 (83), 77 (100), 64 (62), 51 (56).

Synthesis of 3-methyl-4-phenyl-1,2,4-oxadiazole-5(4H)-thione (13): In a nitrogen
atmosphere, 11 (150 mg, 1 mmol) dissolved in anhydrous dioxane (10 mL) was added to TDI
(587.9 mg, 3.3 mmol). The reaction mixture was stirred at 50 °C for 12 hours and the solvent
removed in vacuo afterward. The residue was taken up in DCM and washed three times with
water. The organic layer was dried over Na2SO4 and the solvent removed in vacuo. The crude
residue was purified by flash column chromatography to obtain a pale yellow solid, 150 mg (78
% yield). The solid was further purified by recrystallization using hexane and ethyl acetate.
Yield: 145 mg (78 %). m.p.: 135–137 °C. 
= 0 º (c = 0.5, CDCl3)

1

H-NMR (400 MHz, CDCl3): δ = 2.20 (s, 3H), 7.32–7.35 (td, J=3.8, 1.8 Hz, 2H), 7.57–7.62 (m,

3H). 13C-NMR (100 MHz, CDCl3): δ = 10.4, 124.9, 127.5, 128.5, 130.4, 130.9, 132.6, 167.1
(CN), 186.7 (CS). IR (KBr): ν̃ (cm-1) = 2956, 2914, 1591, 1495, 1348, 1294, 1141. UV λmax
(MeOH): 198, 274 nm. GC-MS (70 eV) m/z (%): 192 (40) [M+], 123 (56), 91 (70), 77 (100), 64
(70), 51 (56).
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Enzyme Inhibition Kinetics
β-lactamase activity, % inhibition and enzyme residual activity determination
Enzyme activity quantitation was performed by spectrophotometric measurement of the
hydrolysis of NCF at 485 nm and at 30°C (∆ε = 20,500 M -1 cm-1). NCF which is a chromogenic
substrate is known to absorb light at 385 nm displaying an orange yellowish color but its
hydrolyzed product absorbs at a much higher wavelength, 485 nm (pinkish red color) (Scheme
1).
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Scheme 1: Hydrolysis of NCF by β-lactamase enzyme

Preparation of MOPS stock solution (0.1M)
8.372 g MOPS was dissolved in 500 mL of water. 0.02 M solution was then made by diluting 40
mL of the stock to 200 mL of water.
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Preparation of BSA (1 % and 0.1 %) in buffer (MOPS)
100 mg of BSA was dissolved in 10 mL of MOPS buffer. 1 % BSA was used for the dilution of
the enzymes. 0.1 % BSA was also made by diluting 1 mL of 1 % BSA in the MOPS buffer in 9
mL of MOPS buffer. 0.1 % BSA was used for actual enzyme kinetics assay.

Substrate (NCF) Preparation (5 mM)
2.582 g of NCF was dissolved in 1 mL of 0.02 M MOPS buffer and further diluted to 100 µM in
enzyme mixture.

Enzyme Preparation (TEM-1 β-lactamase)
Commercially available enzyme (TEM-1) with a concentration of 0.56 mg/mL and molecular
weight of 29.3 kDa from Invitrogen was diluted to 47.5 nM using 1 % BSA and 3 µL was used
for the assay to get the final enzyme concentration to be 0.25 nM.

Enzyme Preparation (P99 β-lactamase)
1.4 mg of commercially available enzyme (P99) with a molecular weight of 39 kDa from SigmaAldrich was dissolved in 1 mL of 1 % BSA in MOPS buffer to make a stock solution of 100
mM. The stock solution was further diluted and used for enzyme kinetics assay.
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In enzyme kinetic assay mixture, NCF was present at 100 µM, TEM-1 was at 0.25 nM,
and P99 was at 0.2 nM in 20 mM MOPS buffer, pH 7.5, with 0.1 % BSA in MOPS buffer in a
final volume of 600 µL. Clavulanate was used as the positive control at a final concentration of
120 nM for the inhibition assay.
Initial rates were monitored for 5 minutes on an Agilent Technologies Cary 8454 UV-Vis
spectrophotometer. Percentage enzyme inhibition was calculated by the formula below:

% enzyme inhibition =

     + ℎ#
x 100 %
     $ℎ% ℎ#

Enzyme residual activity was calculated as:
)  *+,% -./ 0%1 = 100 % − %   ℎ#

52

CHAPTER 3
RESULTS AND DISCUSSION
Lipinski’s Rule of 5 for Drug-likeness
All compounds designed and synthesized during the course of this research were first
tested for conformity to at least two of the 5 Lipinski’s rules for drug-likeness.84,85 As shown in
Table 1, most compounds (1-6 and, 10-13) conformed to at least 2 of all 5 rules with respect to
drug-likeness.

Table 1: Lipinski’s rule of 5 data for compounds 1-6 and, 10-13.
PBD DERIVATIVES
LIPINSKI RULE OF 5
PARAMETERS

1

2

3

4

5

6

10

11

12

13

Clavulanic
acid

Mass (Daltons) [<500]

216

232

257

403

231

259

325

150

176

192

201

High lipophilicity (cLOGP)
[<5]

1.243

2.044

2.334

2.999

1.212

1.092

1.776

1.614

1.977

2.334

-4.057

Hydrogen bond donor [<5]

1

1

1

0

2

1

2

2

0

0

3

Hydrogen bond acceptors
[<10]

4

3

4

6

5

6

3

3

4

2

5

Molar Refractivity [40-130]

59.13

66.72

75.89

112.96

62.67

66.34

94.70

44.28

48.51

53.33

40.42

Drug-likeness, as described by the Lipinski's rule of 5, are based on a number of factors
and it is a qualitative concept used in drug design to ascertain how drug-like a compound is with
regards to its bioavailability.
Lipophilicity of a compound which is a key factor of drug-likeness is the ability of a
compound to be soluble in fat. This is relevant because all orally administered drugs need to first
pass through the intestinal lining after consumption, be carried in the blood which is aqueous and
also penetrate the lipid-based membrane of the cell to reach inside the cell. Lipophilicity is
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usually measured experimentally using a model system or computationally as it was done in this
work where it is termed cLOGP.90
Solubility in water can be estimated from the number of hydrogen bond donors (HBDs)
in a molecule. Low amount of hydrogen bond donors translates to low water solubility which in
turn leads to slow absorption into the blood and action. On the other hand, high amount of HBDs
leads to low fat solubility thus making it difficult for molecules to penetrate the cell membrane to
reach inside the cell. 84,91
The effect of molecular weight stems from the fact that the smaller the molecule, the
better because this directly affects the diffusion of the molecules. Thus, drugs which are less than
500 Daltons in size are known to be usually more efficient in terms of easy diffusion into the
cell.90
As shown in Table 1, all compounds were observed to have low to moderate cLOGP,
molecular weights ranging from 150-403, low HBDs, moderate hydrogen bond acceptors
(HBAs), and molar refractivity ranging from 44.28 – 94.70.
With these positive data in mind, we went ahead to dock the molecules using Sanjeevini
ParDocK. 83

Molecular Docking Results
To gain an insight into the binding mode of some of the PBD derivatives (e.g. 1–13),
ligands made using the free Accelrys Discovery Studio were docked on to TEM-1 β-lactamase
(PDB code: 1LI0) using ParDock83 software from SCFBio, India. To validate the results, known
TEM-1 β-lactamase inhibitor, Clavulanate was also docked onto the enzyme using ParDock.
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Results from molecular docking revealed the interaction of ligands with different amino
acid residues of the active site of TEM-1 β-lactamase are as shown in Table 1 below.

Table 2. Predicted binding affinity, hydrogen bond distances, and active site residues of TEM-1
β-lactamase interacting with ligands.
Predicted distances (Å) of ligands from active site residues
Predicted active site
residues and predicted
binding affinity energies

1

2

3

4

5

6

10

11

12

13

Control
(Clavulanate)

Binding Affinity Energies
(kcal/mol)
SER45
SER105
SER210
LYS48
ASN107
ALA212
ARG218
LYS209
GLU141

-5.10

-5.55

-5.81

-7.14

-6.86

-4.42

-6.51

-3.64

-3.03

-4.05

-4.73

2.66
2.75
-

2.71
2.69
-

3.73
3.21
2.87
-

3.75
2.50
2.20
-

1.55
2.05
1.84
-

1.76
1.71
-

1.89
1.94
1.95
-

2.10
2.48
2.14

3.48
3.59
2.25
-

3.41
-

2.66
2.66
2.79
-

From the data in Table 2, we were able to see the possible interactions between some of
the PBD derivatives and the active site residues of the TEM-1 β-lactamase crystal structure
obtained from the protein data bank. It was observed that the most important catalytic Ser70
(here seen as Ser45) for β-lactam hydrolysis as well as other serine active site residues (Ser105,
Ser210) were found to be interacting with the docked PBD derivatives. Comparing the results
obtained from the docked PBD ligands to the positive control clavulanate, most PBDs had better
predicted binding affinity energies ranging from – 3.03 to – 7.14 kcal/mol compared to
clavulanate which had a binding affinity energy of – 4.73 kcal/mol. Binding affinity energy was
calculated based on the formation of simulated hydrogen bonding and other non-covalent
interactions between the ligands (inhibitors) and active site residues. Similar active site residues

55

were observed to be interacting and forming hydrogen bonds at distances mostly < 3 Å as shown
in Figure 16–20.

Figure 16: Interaction between TEM-1 β-lactamase active site residues and Clavulanic acid

Compound 5, 6 and 11 had the best hydrogen bond distances (shortest) (1.55 and 2.10 Å
respectively) in their interaction with important active site residue Ser 45. Compound 6 was also
shown to interact with about the same closeness with Ser105 (1.71 Å). These bond distances
were indicative of the relative closeness of these important active site residues to the ligand thus
leading us to believe that these derivatives may interact more easily with active site residues.
This is due to the non-covalent interactions (hydrogen bonding) observed during docking. Based
on these potentially positive results due to the simulated binding affinity energies and
interactions, all proposed PBD and N-phenylacetamide derivatives were synthesized.
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Figure 17: Interaction between TEM-1 β-lactamase active site residues and 2

Figure 18: Interaction between TEM-1 β-lactamase active site residues and 3
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Figure 19: Interaction between TEM-1 β-lactamase active site residues and 4

Figure 20: Interaction between TEM-1 β-lactamase active site residues and 6
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Syntheses of PBD derivatives
Synthesis of PBD Cyclic Amidine (3)
Pyrrolo[2,1-c][1,4]benzodiazepine natural product (1) (from Isatis indigotica 63) was
made as the starting material for all other derivatives by refluxing isatoic anhydride with (L)proline in DMF following literature procedures (Scheme 1).92,93 After recrystallization from
Acetone/DMF (v/v 10:1) (yield = 82%), 1H NMR in DMSO-d6 showed six multiplets for the
three (-CH2) groups on the pyrrolidine ring (1.78–3.59 ppm), a doublet for the C-11a proton
(4.10–4.13 ppm), two each of doublet-doublet and doublet-doublet-doublet for the aromatic
protons (7.1–7.8 ppm) and a singlet representing the (–NH) group (10.51 ppm) (Appendix A1).
13

C NMR, IR, and GC-MS were also used to further confirm the structure of the product

1. IR spectrum showed amide stretches at 1621 cm-1 and 1691 cm-1 confirming the presence of
the two amide carbonyl groups present in 1. Both amide carbonyl groups were also represented
by peaks at 165.1 and 171.3 ppm in the 13C NMR also helping to confirm that the product was
PBD dilactam (1). In GC-MS, parent peak was observed at a retention time (R.T) of 13.4
minutes with a peak area of 99.69 % which indicated the exact molecular weight of the desired
compound (1) (Appendix A2–A4).
Monothiolactam (2) was synthesized with a good yield by the thionation of 1 in THF at
room temperature for 28 hours with 2,4-bis-(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane2,4-disulfide (Lawesson’s reagent).94 Acetone/DMF (v/v 20:1) was used for the recrystallization
of monothiolactam. 1H NMR in DMSO-d6, 13C NMR, IR, and GC-MS was used to confirm that
the product was properly thionated (Appendix B1–B4). IR peak for one of the amide carbonyl
was shown to have been removed (Appendix B4) indicating that the carbonyl of the amide at
1691 cm-1 had been thionated. Other characteristic features of 1 also present in 2 were observed
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in the 1H NMR and 13C NMR, however with slightly different chemical shifts. Only one amide
carbonyl was observed in the 13C NMR at 164.8 ppm and the second peak at 202.6 ppm, which
was indicative of the conversion of the C=O into a C=S thus confirming thionation (Appendix
B1–B2). R.T and peak area of 2 in GC – MS was 14.6 and 99.30 %, respectively, also indicative
of the molecular weight of the desired compound (2); although a little amount of the starting
material (1) was observed to still be present in the sample. (Appendix B3).

Scheme 2: Synthesis of PBD Dilactam (1) and Thiolactam (2)

The monothiolactam (2) was then reacted with an amine (propylamine) in the presence of
mercury(II)chloride (HgCl2) to the cyclic amidine 3 in high yields.
IR showed medium stretch (3356 cm-1) for 3 indicating the replacement of the thio group
in 2 by an amine (3) group (Appendix C4). 13C NMR also showed the replacement of the thio
(C=S) peak previously at 202.6 ppm with a new amino peak at about 43 ppm in 3. The propyl
group introduced were also observed as new peak at chemical shifts between 10–40 ppm in 3
(Appendix C2)
GC – MS showed a parent peak at an R.T. of 15.0 minutes and a peak area of 97.14 % for
3 (Appendix C3).
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Scheme 3: Synthesis of PBD propyl cyclo amidine (3)

Scheme 4. Mechanism for synthesis of PBD cyclo amidine

Synthesis of PBD oxopyrimidine (4)
Neat reaction (without the use of solvent; performed in a Zincke apparatus) of the
amidine 3 with bis(2,4,6-trichlorophenyl)-2-phenylmalonates resulted in the formation of
the pyrimidine-annulated pyrrolobenzodiazepine 4 with the leaving group 2,4,6trichlorophenol being distilled off during the reaction.95
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1

H NMR in DMSO-d6 showed the introduction of a singlet proton at 4.91 ppm in 4

which is indicative of the phenylic proton from the malonic ester’s introduction into the PBD
(Appendix D1). Overlapping of duplicate aromatic protons indicating the presence of new
aromatic protons were also observed from 7.30 to 8.05 ppm in 4. The peak for the C11a proton
which was present in 3 was absent in the 1H NMR for 4 due to the presence of a double bond
between C11 and C11a (Appendix D1).
13

C NMR also confirmed the presence of extra carbons (125.5–133.3 ppm for 4) in the

aromatic region of the 13C NMR introduced due to the presence of the new phenyl ring from the
malonic ester’s introduction. New carbonyl carbons were also introduced (Appendix D2).
IR and GC-MS were also used to further confirm the structure of the product (1)
(Appendix D3 – D4).
GC-MS showed R.T, molecular weight and peak area of 4 to be 29.1 minutes, 401 g mol1

, and 99.34 %, respectively, indicating the formation of the desired product 4 (Appendix D3).
Results from previous studies have shown the possible existence of enolic partial

structures in 4 in DMSO-d6 and CDCl3 at room temperature and hence the possibility of
tautomers.95
In general, the reaction of N, N´-disubstituted amidines with bis(2,4,6-trichlorophenyl)
malonates has been shown to result in the formation of pyridinium-4-olates. Ring closure by the
loss of two molecules of trichlorophenol through a ketene intermediate as shown below is
thought to be one of the possible explanation for the syntheses of these compounds
mechanistically (Scheme 5).95 To be taken into account is also the fact that this is the first time
compound 4 has been synthesized and crystallized.
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Scheme 5: Synthesis of PBD oxopyrimidine (4)

Scheme 6: Proposed mechanism for the formation of PBD oxo pyrimidine 4 (Adapted from
Shilabin, 2005) 95.

Synthesis of PBD oxime (5)
A slight modification of the protocol used in Rekowski et al. 2010 and Bartsch et al.
1989 for the synthesis of 5 was employed. 96,97 Compound 5 was formed by a nucleophilic
63

substitution of 2 using NH2OH·HCl under basic conditions. In place of triethylamine, K2CO3 was
used in this reaction as the base. The product was formed after 24 hours of stirring at room
temperature and further purified by flash column chromatography.
IR spectra confirmed the introduction of an OH group (3281 cm-1) into the PBD as well
as the presence of an OH proton in the proton NMR at 8.75 ppm. The presence of the newly
introduced NH peak was also represented by a singlet at 10.08 ppm (Appendix E1 and E4).
GC-MS confirmed the desired product (5) with a molecular weight of 231 g mol-1 by an
R.T. of 14.5 minutes and a peak area of 44.6 %. However, a possible reversion to 1 from some of
the starting material 2 was observed as indicated by a molecular weight of 216 g mol-1 with a
peak area of 49.8 % at R.T of 13.3 minutes which is the same R.T. for 1 (Appendix E3).

Scheme 7: Synthesis of PBD oxime (5)

The % yield of the reaction improved drastically from 76% reported in literature97 to 94
% with the change in the base from triethylamine to K2CO3.
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Synthesis of PBD oxadiazole (6 and 7)
PBD oxadiazole (6)96 and thionyl oxadiazole (7) were formed through carbonylative and
thionylative reactions, respectively. PBD oxime (5) was treated with 1,1-carbonyl diimidazole
(CDI) and 1,1-thionyl diimidazole (TDI) and refluxed in dioxane for 12 hours respectively. The
change in the solvent from THF to dioxane made the reaction faster and more efficient. The
reaction with THF according to literature occurs in 24 hours and produces a yield of 84 %.97 The
modification leads to the formation of 6 and 7 in 12 hours with yields of 88 % and 90 %,
respectively.
1

H NMR of 6 and 7 in CDCl3-d revealed the retention of the aromatic protons as well all

other protons present in the starting material 5 except the NH and OH peaks which were now
absent in 6 and 7, respectively, due to the introduction of the oxadiazolinone ring (Appendix F1
and G1). Formation of desired products 6 and 7 was also confirmed using IR which showed the
introduction of a new C=O stretch at 1786 cm-1 in 6 replacing the OH stretch in 5 at 3281 cm-1.
This comes in addition to the previously present C=O stretch observed at 1612 cm-1 in 5 which is
also represented by a stretch of 1640 cm-1 in 6. The absence of the OH at 1612 cm-1 from 5 in 7
also indicates its possible replacement by a thione (C=S which is not observable in an IR spectra)
as intended by the synthetic approach employed for the synthesis of 7. This is also confirmed by
the absence of the new C=O group introduced in 6 (Appendix F4 and G4). Characteristic
molecular weights for compound 6 (257 g mol-1) and 7 (273 g mol-1) were observed in their
respective GC-MS spectra at 14.9 minutes with a peak area of 62.94 % for 6 and 15.6 minutes
with a peak area of 63.49 % for 7 (Appendix F3 and G3).
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Scheme 8: Synthesis of PBD oxadiazole (6) and (7)

Crystals of compound 6 and 7 which have not been published in literature before now
were also formed.
In order to gain additional insights into the structure of 6, we tried to obtain single
crystals for an X-ray analysis. We were finally successful in that: by slow evaporation of a
concentrated solution of 6 in a 1:1 mixture of diisopropyl ether and ethyl acetate, we were able to
crystallize 6. The elemental cell contains one molecule of the PBD oxadiazole. The molecular
structure and crystallographic numbering of 6 are shown in Figure 21 below.
The conformation adopted by 6 according to the X-ray diffraction ORTEP structure was
a twisted conformation which is synonymous with 6:7:5 pyrrolobenzodiazepine ring systems.
The 7 membered ring in this structure adopts a boat arrangement which is confirmed by bond
angles of N(2)-C(8)-C(9) and C(8)-N(2)-C(7) which were determined to be 119.90 (19º) and
126.35 (2º), respectively. The C(8)-N(3) bond length is 128.8 pm which corresponds to an imino
C(sp2)=N(sp2) double bond. On the other hand, the N(2)-C(8) represents a single bond which has
a bond length of 136.9 pm. The distinct C(8)-C(9) single bond present in the structure with a
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bond length of 149.5 pm excludes the formation of an optically inactive tautomer of 6 (Appendix
N1).

C(8)–N(3) = 128.8 pm
N(2)–C(8) = 136.9 pm
Figure 21: X-ray diffraction ORTEP structure and cell unit of compound 6.

Synthesis of Thioacetamide (8) and N-phenylacetamide Cyclic Amidine (9)
N-phenylacetamide which is readily available was used as the starting material for the
synthesis of other derivatives by the thionation in DCM at room temperature for 4 hours with
Lawesson’s reagent.98
1

H NMR in CDCl3-d showed four sets of non-equivalent protons for the aromatic protons

and the methyl group proton. The methyl protons were indicated by a singlet of 3H at 2.16 ppm
and the aromatic protons were between 7.09–7.51 ppm (Appendix H1). Aromatic carbons were
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indicated by chemical shifts between 120 to 138 ppm in 13C NMR, while the methyl carbon, as
well as the thioamide carbon, were represented by peaks at 24.7and 168.6 ppm, respectively
(Appendix H2). IR indicated the absence of the carbonyl peak in the starting material
(acetanilide) and the retention of the NH peak which could be seen at about 3175 cm-1 (Appendix
I4). GC-MS further confirmed the structure of the product (8) with a parent peak of 151 g mol-1
at 9.7 minutes and a peak area of 96.6 % which is in correspondence with the molecular weight
of the expected product (Appendix H3).
After thionation, thioacetamide (8) was reacted with propyl amine to yield (E)-N-phenylN'-propylacetimidamide (9) which was a liquid with a boiling point of about 150 °C. This
reaction was accomplished after 3 different reaction conditions ranging from reflux temperature
to 0 °C in the presence of mercury(II)chloride. The highest yield was obtained by carrying out
the reaction at 0 °C.
13

C NMR showed the introduction of new carbon moieties from the propylamine into the

structure of 9 with a new peak at chemical shifts between 11 and 68 ppm. The carbon positioned
between the two nitrogen groups was very much deshielded thus showing a peak at about 207
ppm (Appendix I2). 1H NMR in CDCl3-d showed the introduction of three new sets of nonequivalent protons at chemical shifts 0.96-1, 1.57- 1.66, and 3.28-3.32 ppm, respectively, which
was indicative of the newly introduced propyl chain. An extra proton at 1.19 ppm was observed
and this was representative of the -NH proton. Every other proton as in starting material 8, were
all accounted for but at different chemical shifts as they were in 8 (Appendix I1).
GC-MS confirmed the synthesis of the desired product, 9 with a parent peak of 176 g
mol-1 at 9.3 minutes and a peak area of 96.84 % corresponding to the molecular weight of the
desired product, 9 (Appendix I3).
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Scheme 9: Synthesis of thioacetamide (8) and N-phenylacetamide cyclic amidine (9)

Synthesis of 2-methylene-1,5-diphenyl-3-propyldihydropyrimidine-4,6(1H,5H)-dione (10)
(E)-N-phenyl-N'-propylacetimidamide (9) was used to prepare 10, using the same neat
reaction (performed in a Zincke apparatus) used for the synthesis of PBD oxo pyrimidines (4).
Bis(2,4,6-trichlorophenyl)-2-phenylmalonate was reacted with 9 leading to the formation of
compound 10 with the 2,4,6-trichlorophenol being distilled off during the reaction.
13

C NMR showed the introduction of new carbonyl peaks as a result of the malonic ester

introduction at chemical shifts of 150 and 168 ppm, respectively. Overlapping aromatic carbon
peaks were also observed in aromatic carbon region represented by an increase in peak sizes
(Appendix J2). 1H NMR in CDCl3-d confirmed the introduction of a singlet proton at 4.10 ppm
and new aromatic protons at the aromatic region (Appendix J1). IR confirmed the introduction of
the C=O groups with a very sharp C=O stretch at 1643 cm-1 (Appendix J4). Finally, GC-MS was
also used to confirm the structure of the compound (10) obtained with a molecular peak at about
322 coming at retention times of 18.9 and 18.93 with peak areas of 55.5 % and 45.5 %
(Appendix J3).
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Scheme 10: Synthesis of 10

Synthesis of (E)-N'-hydroxyl-N-phenylacetimidamide (11)
Two different synthetic routes were employed for the synthesis of 11. The first route
employed was similar to that used for the formation of compound 5, where 11 is formed by
nucleophilic substitution of 8 with NH2OH·HCL in the presence of a mild base (Na2CO3).
The yield was fairly lower (55 % yield) when compared to the other synthetic procedure
that had been reported in literature for the synthesis of 11.99
In the second synthetic route, aniline was reacted with nitroethane in the presence of
polyphosphoric acid (PPA). The reaction was quenched and neutralized after 5 hours using H2O
and then NH3 (aq), respectively, and the final product, 11 recrystallized afterward from water.
The yield for this procedure was 75 % which was similar to the yield gotten from literature.99
The mechanism for the second synthetic route occurs through an umpolung activated
nitroalkane formed from the addition of the PPA to the nitroalkane to form an electrophilic
phosphorylated aciform of the nitroalkane. This umpolung activated nitroalkane is then attacked
by electron-rich arene (aniline).99
Oxime intermediates are formed after the subsequent elimination of H3PO4. It is
rationalized that anilines can also be employed in a similar transformation as nitrogen-based
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nucleophiles to produce imidamides as shown in Scheme 10, which can further be employed as
convenient building blocks for the synthesis of heterocyclic compounds.99
1

H NMR, 13C NMR, IR, and GC-MS were used to further confirm the structure of both

products (11) (Appendix K1 – K4).
GC-MS showed a molecular peak of 150 coming at a retention time of 8.9 (Appendix
K3).

Scheme 11: Synthesis of (E)-N'-hydroxyl-N-phenylacetimidamide (11)

Scheme 12: Mechanism for the alternative synthesis of (E)-N'-hydroxyl-N-phenylacetimidamide
(11) (Adapted from Aksenov et al. 2015).99
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Synthesis of N-phenyl oxadiazoles (12 and 13)
N-phenyl oxadiazoles (12 and 13) were also formed through carbonylative and
thionylative reactions, respectively, just like their PBD counterparts. In these reactions, however,
dioxane was used as the solvent and the reaction temperature was reduced to 50 oC. Crystals of
compound 12 and 13 were also recovered from a mixture of diisopropyl ether and ethyl acetate.
1

H NMR in CDCl3-d showed aromatic protons as well as only the methyl group protons

which were conserved in both 12 and 13. The OH proton observed in 12 was no longer present
showing that 12 and 13 were formed (Appendix L1 and M1). 13C NMR reveals new C=O and
C=S peaks for 12 and 13 at 156.2 and 186.7 ppm, respectively. (Appendix L2 and M2). IR
confirmed the replacement of the OH in 11 by the removal of the OH stretch (Appendix K4, L4,
and M4). GC – MS showed peaks at 10.1 and 12.3 minutes for 12 and 13, respectively.
Molecular peaks of 176 and 192 g mol-1 were also observed for 12 and 13 with peak areas of
96.26 % and 62.11 % (Appendix L3 and M3).

Scheme 13: Synthesis of N-phenyl oxadiazole (12) and (13)
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Enzyme Inhibition Kinetics
Enzyme inhibition kinetics to ascertain the percentage inhibition and residual activity of
the enzymes TEM-1 and p99 lactamase was carried out in 20 mM MOPS buffer. 3 µL (final
concentration = 0.25 and 0.20 nM for TEM-1 and P99 respectively) of enzymes was used for the
assay. Percentage inhibition and residual activities of the enzymes after incubation with
inhibitors (1-13) in the presence of chromogenic substrate NCF is shown in Tables 3 – 6 below.

Figure 22: Typical hydrolysis of substrate, NCF by TEM-1 β-lactamase
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Table 3: Residual Activity (%) and percent inhibition of TEM-1 after incubation with
clavulanate and PBD derivatives for 5 minutes, 30 o C in DMF (3%).
Enzyme Inhibition Kinetics
Conditions
Clavulanate #

Vo ± SD (∆A, s-1) x 10-4
2.3721 ± 0.0179

Vi ± SD (∆A, s-1) x
10-4
0.6112 ± 0.0091

Residual Activity
(%)
25.77

%
Inhibition
74.23

1
2
3
4
5
6
7

2.3721 ± 0.0179
2.3721 ± 0.0179
2.3721 ± 0.0179
2.3721 ± 0.0179
2.3721 ± 0.0179
2.3721 ± 0.0179
2.3721 ± 0.0179

1.5667 ± 0.01686
2.5101 ± 0.08144
2.6475 ± 0.04724
2.0864 ± 0.01605
1.5617 ± 0.01740
2.1298 ± 0.02806
2.1795 ± 0.02172

66.05
100
100
87.96
65.83
89.79
91.88

33.95
NI
NI
12.04
34.17
10.21
9.22

Table 4: Residual Activity (%) and percent inhibition of P99 after incubation with clavulanate
and PBD derivatives for 5 minutes, 30 o C in DMF (3%).
Enzyme Inhibition Kinetics
Conditions
Clavulanate#

Vo ± SD (∆A, s-1) x
10-4
2.5743 ± 0.01647

Vi ± SD (∆A, s-1) x
10-4
2.277 ± 0.03676

Residual Activity (%)

% Inhibition

88.45

11.55

1
2
3
4

2.5743 ± 0.01647
2.5743 ± 0.01647
2.5743 ± 0.01647
2.5743 ± 0.01647

3.9885 ± 0.04783
3.802 ± 0.08103
3.4348 ± 0.01447
2.2329 ± 0.01290

100
100
100
86.74

NI
NI
NI
13.36

5

2.5743 ± 0.01647

2.6279 ± 0.03439

100

NI

6

2.5743 ± 0.01647

2.2965 ± 0.02968

89.24

10.76

7

2.5743 ± 0.01647

2.4733 ± 0.02748

96.08

3.92

#

Final concentration and volume of Clavulanate = 120 nM
Final concentration & volume of Enzyme (TEM-1) = 3 µL (0.25 nM)
Final concentration & volume of Enzyme (P99) = 3 µL (0.20 nM)
Substrate (NCF) = 12 µL (100 µM), Triton X100 = 3 µL (0.1 %), 0.1 % BSA in MOPS buffer = 562 µL (0.02 M, pH 7.5)
Inhibitor (in 3 % DMF) = 20 µL (400 µM), NI = No inhibition

Table 5: Residual Activity (%) and percent inhibition of TEM-1 after incubation with
clavulanate and N-phenylacetamide derivatives for 5 minutes, 30 o C in DMF (3%).

11

Vo ± SD (∆A, s-1) x
10-4
3.7575

Vi ± SD (∆A, s-1) x
10-4
4.2356

Residual Activity
(%)
100

%
Inhibition
NI

12

3.7575

4.6721

100

NI

13

3.7575

3.3132

88.18

11.82

Enzyme Inhibition Kinetics Conditions

Final concentration & volume of Enzyme (TEM-1) = 3 µL (0.25 nM)
Final concentration & volume of Enzyme (P99) = 3 µL (0.20 nM)
Substrate (NCF) = 10 µL (50 µM), Triton X100 = 3 µL (0.1 %), 0.1 % BSA in MOPS buffer = 562 µL (0.02 M, pH 7.5)
Inhibitor (in 3 % DMF) = 20 µL (1 mM), NI = No inhibition
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Table 6: Residual Activity (%) and percent inhibition of P99 after incubation with clavulanate
and N-phenylacetamide derivatives for 5 minutes, 30 o C in DMF (3%).
Enzyme Inhibition Kinetics
Conditions
11

Vo ± SD (∆A, s-1) x
10-4
4.4748

Vi ± SD (∆A, s-1) x 10-

12
13

4.5517

Residual Activity
(%)
100

%
Inhibition
NI

4.4748

4.6837

100

NI

4.4748

5.0231

100

NI

4

Final concentration & volume of Enzyme (TEM-1) = 3 µL (0.25 nM)
Final concentration & volume of Enzyme (P99) = 3 µL (0.20 nM)
Substrate (NCF) = 10 µL (50 µM), Triton X100 = 3 µL (0.1 %), 0.1 % BSA in MOPS buffer = 562 µL (0.02 M, pH 7.5)
Inhibitor (in 3 % DMF) = 20 µL (1 mM), NI = No inhibition

From the enzyme kinetics results, it was observed that all derivatives of PBD and Nphenylacetamide had little or no inhibiting effects on the enzymes studied in this study. For
PBDs, 5 has the highest percentage inhibition of 34.17 % for TEM-1 β-lactamase but had no
effect on P99 at a final concentration of 400 µM. 4, 6, and 7 also showed percentage inhibition of
TEM-1 β-lactamase of 12.04 %, 10.21 %, and 9.22 %, respectively. This relative inhibition was
replicated in P99 β-lactamase; 13.36, 10.76, and 9.21 % for 4, 6, and 7 respectively. It is
suspected that there might be issues with the solubility of the inhibitors in the buffer solution
used for the enzyme kinetics reactions thus making the inhibitor unavailable to the active site.
There is also a possibility of steric interference being another setback preventing the
active part of the molecules from interacting appropriately with the active site of the enzymes.
We believe that incorporation of groups that enhance solubility (e.g. COOH, SO3-, OH) would be
key to improving the inhibitory activity of the inhibitors against the enzymes. Derivatives 8-13
were made to try to tackle the possible steric hindrance problem and possibly increase
electrophilicity and interaction between active site residues and the inhibitors. However, after in
vivo assays, only 13 showed some activity against TEM-1 β-lactamase with a percentage
inhibition of 11.82 % at a final concentration of 1 mM.
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We believe that the attachment of a phenyl group to the nitrogen group as shown in 12
and 13 leads to the formation of very stable intermediates due to the resonance stabilization
effected by the phenyl ring. This stabilization could thus prevent the OH nucleophile from the
splitting of water to catalyze the remainder of the reaction of hydrolysis thus leading to the
inhibitor being released from the active site of the enzymes. For future work, in addition to
improving solubility by the addition of COOH, SO3, and OH groups to the derivatives, we aim to
also change the position the phenyl group in the latter derivatives (8-13) to allow better
interaction of the active site residues (Ser 45 and Ser 105) with the oxadiazole ring particularly in
12 and 13 as well as reduce the resonance stabilizing effect of the phenyl ring on the derivatives
12 and 13.
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CHAPTER 4
CONCLUSION AND FUTURE WORK
Conclusion
In this project, various derivatives of PBD were synthesized, using commercially
available starting materials like PBD dilactam (1) (formed from isatoic anhydride and L-proline)
and N-phenylacetamide and evaluated for their efficacy as non-β-lactam β-lactamase inhibitor.
The PBD derivatives were: (S)-11-thioxo-1,2,3,10,11,11a-hexahydro-5Hbenzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (2), (S)-11-amino-1,2,3,11a-tetrahydro-5Hbenzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (3a), (S)-11-(propylamino)-1,2,3,11a-tetrahydro-5Hbenzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (3b), (14aS)-3-phenyl-12,13,14,14a-tetrahydro2H,10H-benzo[e]pyrimido[2,1-c]pyrrolo[1,2-a][1,4]diazepine-2,4,10(3H)-trione (4), 3-phenyl-1propyl-1,12,13,14-tetrahydro-2H,10H-benzo[e]pyrimido[2,1-c]pyrrolo[1,2-a][1,4]diazepine2,4,10(3H)-trione (5), (S,E)-11-(hydroxyimino)-1,2,3,10,11,11a-hexahydro-5Hbenzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (6), (S)-11,12,13,13a-tetrahydro-3H,9Hbenzo[e][1,2,4]oxadiazolo[3,4-c]pyrrolo[1,2-a][1,4]diazepine-3,9-dione (7) and (S)-3-thioxo11,12,13,13a-tetrahydro-3H,9H-benzo[e][1,2,4]oxadiazolo[3,4-c]pyrrolo[1,2-a][1,4]diazepin-9one (8).
The N-phenylacetamide derivatives were: N-phenylethanethioamide (9), (E)-N-phenylN'-propylacetimidamide (10), 2-methylene-1,5-diphenyl-3-propyldihydropyrimidine4,6(1H,5H)-dione (11), (E)-N'-hydroxy-N-phenylacetimidamide (12), 3-methyl-4-phenyl-1,2,4oxadiazol-5(4H)-one (13) and 3-methyl-4-phenyl-1,2,4-oxadiazole-5(4H)-thione (14).
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Docking studies were also conducted to determine the possible interaction of PBD
derivatives with active site amino acid residues revealed significant interactive spanning of the
active site of TEM-1 β-lactamase by PBD-derivatives. This indicated the high possibility of
being high potentials at being a new class of non-β-lactam β-lactamase inhibitors due to their
non-covalent interactions with active site residues of the enzyme. Molecular docking results
showed the possibility of some PBDs derivatives, particularly compounds 4, 5, and 7 having the
best potentials of being non-β-lactam β-lactamase inhibitors due to their interaction with the
enzymes’ active site residues and predicted binding affinity energies. Compound 4 displayed the
best potential interaction in terms of the number of active site residues, as well as hydrogen
bonding forces. However, possible steric hindrances to more efficient interactions were thought
to be encountered during docking due to the bulky nature of the PBD molecules thus limiting
optimal interactions. This was also observed in the percentage inhibition recorded during enzyme
kinetics reaction with TEM-1 and P99 β-lactamases.
Based on the poor inhibitory activities of the PBD derivatives observed during the
enzyme kinetics experiment, we proposed some possible reasons for this poor results The poor
inhibitory activities of the PBD derivatives could have been as a result of poor solubility of the
compounds in the solvent used that is DMF, thus availability of the inhibitor molecules to the
enzymes. Another possible reason for the low inhibitory activities observed from compounds 113 could be the incubation time of the reaction which was 5 minutes. This could possibly not be
sufficient enough time for the enzyme and inhibitors to interact appropriately to bring about
maximum inhibition. In future work, we would also extend the incubation time of the inhibitor
with the enzymes before the addition of the substrate, NCF.
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The mechanism of action which we proposed at the beginning of the work could be
different from the mechanism by which the inhibitor interacts with enzymes thus facilitating easy
release of the inhibitor by the enzyme after initial interaction. This could imply that PBDs
possibly do not for covalent interactions as in β-lactam based inhibitors like clavulanate but
rather form non-covalent interactions which are readily susceptible to being reversible.
Optimization of enzyme kinetics assay parameters such as reaction temperature, solvent
changes to enhance possible solubility and hence bioavailability of ligands to enzymes, reaction
times as well as buffer change would also be done in the future to further rule out these
possibilities as reasons for the poor inhibitory activities of the inhibitors.
The search for more elaborate PBD chemotypes which may have better activity as well as
stronger affinity, exploiting fragment-based designing followed by synthesis and further in vitro
evaluation against TEM-1 and P99 β-lactamases will be done in the future.
Future Work
1. Assay a library of compounds in search of better lead compounds for β-lactamase
inhibition. This would be done to help get lead compounds that would spearhead the
synthesis of new and better inhibitors.
2. The introduction of functional groups like carboxylic acid groups that will further
enhance the solubility of the inhibitors in the enzyme assays solution to enhance further
interactions.
3. Substituting the methyl group on the latter derivatives (8-13) with a phenyl group and the
removal of the phenyl group from being attached to the amide group as shown in the
Figure 23 below will further possibly enhance interactions of inhibitors with enzymes.
79

Figure 23: Proposed derivatives for future work
4. Depending upon the results of the assay, design and synthesize new β-lactamase
inhibitors.
5. Check the efficacy of the PBD compounds and all other synthesized compounds on
cytotoxic activity and inhibition of other enzymes (e.g. ACE) implicated in diseases and
infections.
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Appendix B1: 1H NMR Spectrum for Compound 2 in DMSO-d6
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O
N
H

N
O

N
O

116

F4: IR Spectrum for Compound 6 in Chloroform
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Appendix G1: 1C NMR Spectrum for Compound 7 in Chloroform-d
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Appendix G2: 13C NMR Spectrum for Compound 7 in Chloroform-d
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Appendix G3: GC-MS Spectrum for Compound 7 in Chloroform
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Appendix G4: IR Spectrum for Compound 7 in Chloroform
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Appendix H1: 1H NMR Spectrum for Compound 8 in Chloroform-d
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Appendix H2: 13C NMR Spectrum for Compound 8 in Chloroform-d
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Appendix H3: GC-MS Spectrum for Compound 8 in Chloroform
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Appendix I1: 1H NMR Spectrum for Compound 9 in Chloroform-d
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Appendix I2: 13C NMR Spectrum for Compound 9 in Chloroform-d
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Appendix I3: GC-MS Spectrum for Compound 9 in Chloroform-d
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Appendix J1: 1H NMR Spectrum for Compound 10 in Chloroform-d
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Appendix J2: 13C NMR Spectrum for Compound 10 in Chloroform-d
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Appendix J3: GC-MS Spectrum for Compound 10 in Chloroform
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Appendix J4: IR Spectrum for Compound 10 in Chloroform
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Appendix K1: 1H NMR Spectrum for Compound 11 in Chloroform-d
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Appendix K2: 13C NMR Spectrum for Compound 11 in Chloroform-d
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Appendix K3: GC-MS Spectrum for Compound 11
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Appendix L1: 1H NMR Spectrum for Compound 12 in Chloroform-d
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Appendix L2: 13C NMR Spectrum for Compound 12 in Chloroform-d
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Appendix L3: GC-MS Spectrum for Compound 12 in Chloroform
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Appendix L4: 1H NMR Spectrum for Compound 12 in Chloroform-d
N

N
O
O

141

Appendix M1: 1H NMR Spectrum for Compound 13 in Chloroform-d
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Appendix M2: 13C NMR Spectrum for Compound 13 in Chloroform-d
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Appendix N1: Crystal data, structure refinement, Bond lengths [Å] and angles [°] for 6
Table 7: Crystal data and structure refinement for 6.
Identification code

6

Empirical formula

C13H11N3O3

Formula weight

257.25

Temperature

100.00(10) K

Wavelength

0.71073 Å

Crystal system

Monoclinic

Space group

I121

Unit cell dimensions

a = 14.6877(6) Å

= 90°.

b = 6.8905(3) Å

= 91.751(4) °.

c = 11.5288(5) Å

 = 90°.

Volume

1166.23(8) Å3

Z

4

Density (calculated)

1.465 Mg/m3

Absorption coefficient

0.107 mm-1

F (000)

536

Crystal size

0.2255 x 0.1477 x 0.108 mm3

Theta range for data collection

3.445 to 32.367°.

Index ranges

-21<=h<=21, -9<=k<=10, -16<=l<=16

Reflections collected

10951

Independent reflections

3882 [R(int) = 0.0435]

Completeness to theta = 30.000°

99.7 %

Absorption correction

Semi-empirical from equivalents

Max. and min. transmission

1.00000 and 0.95967

Refinement method

Full-matrix least-squares on F2

Data / restraints / parameters

3882 / 1 / 172

Goodness-of-fit on F2

1.028

Final R indices [I>2sigma(I)]

R1 = 0.0518, wR2 = 0.0954

R indices (all data)

R1 = 0.0631, wR2 = 0.1003

Absolute structure parameter

-0.9(7)

Extinction coefficient

n/a

Largest diff. peak and hole

0.262 and -0.227 e.Å-3

146

Table 8: Bond lengths [Å] and angles [°] for 6.
_____________________________________________________________________________________________
O(1)-C(1)

1.226(3)

N(2)-C(8)

1.369(3)

C(5)-C(6)

1.382(4)

O(2)-C(10)

1.202(3)

N(2)-C(10)

1.386(3)

C(6)-C(7)

1.386(3)

O(3)-N(3)

1.441(3)

N(3)-C(8)

1.288(3)

C(8)-C(9)

1.495(3)

O(3)-C(10)

1.358(3)

C(1)-C(2)

1.508(3)

C(9)-C(11)

1.525(3)

N(1)-C(1)

1.348(3)

C(2)-C(3)

1.398(3)

C(11)-C(12)

1.528(3)

N(1)-C(9)

1.468(3)

C(2)-C(7)

1.401(3)

C(12)-C(13)

1.526(3)

N(1)-C(13)

1.470(3)

C(3)-C(4)

1.379(4)

N(2)-C(7)

1.424(3)

C(4)-C(5)

1.386(4)

C(10)-O(3)-N(3)

109.94(17)

N(1)-C(9)-C(11)

103.83(17)

C(1)-N(1)-C(9)

125.75(18)

C(8)-C(9)-C(11)

113.24(19)

C(1)-N(1)-C(13)

122.07(18)

O(2)-C(10)-O(3)

124.2(2)

C(9)-N(1)-C(13)

112.18(17)

O(2)-C(10)-N(2)

130.2(2)

C(8)-N(2)-C(7)

126.35(18)

O(3)-C(10)-N(2)

105.6(2)

C(8)-N(2)-C(10)

107.0(2)

C(9)-C(11)-C(12)

103.84(18)

C(10)-N(2)-C(7)

126.6(2)

C(13)-C(12)-C(11)

103.43(19)

C(8)-N(3)-O(3)

103.95(18)

N(1)-C(13)-C(12)

103.09(1)

O(1)-C(1)-N(1)

121.8(2)

O(1)-C(1)-C(2)

119.7(2)

N(1)-C(1)-C(2)

118.52(18)

C(3)-C(2)-C(1)

116.0(2)

C(3)-C(2)-C(7)

117.5(2)

C(7)-C(2)-C(1)

126.4(2)

C(4)-C(3)-C(2)

121.4(2)

C(3)-C(4)-C(5)

120.0(2)

C(6)-C(5)-C(4)

120.0(2)

C(5)-C(6)-C(7)

119.8(2)

C(2)-C(7)-N(2)

121.28(19)

C(6)-C(7)-N(2)

117.4(2)

C(6)-C(7)-C(2)

121.3(2)

N(2)-C(8)-C(9)

119.90(19)

N(3)-C(8)-N(2)

113.47(19)

N(3)-C(8)-C(9)

126.6(2)

N(1)-C(9)-C(8)

107.49(17)
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